On Saturday, in the statement, the manufacturer informed that the serum Institute of India is ready to restart coronavirus vaccine trials which were put on hold. Pending permission from the drug controller general of India.
The countries drug controller DCGI issued a notice to the Serum Institute which is headed by Adar Poonawalla. As per the notice, it questioned why it was continuing the trials in India though it has been stopped elsewhere. It also questioned why it has not received a report detailing the symptoms of the patient in the UK.
Regarding the notice, the Serum Institute responded with a statement that “we are reviewing the situation and pausing India trials till AstraZeneca restarts the trial”. The statement further that “we are following DGCI instructions and will not be able to comment further on trials. You can connect with DGCI for more updates in this front”.
The coronavirus vaccine developed by the Oxford University along with plasma major AstraZeneca which is manufactured by the Serum Institute of India wood stop phase III trials that were likely to begin in India next week. After the volunteers in the UK showed some potentially adverse symptoms, The AstraZeneca stopped vaccine trials across the four Nations as a precautionary measure.